18F-FDG-PET/CT response assessment in patients with advanced melanoma treated with combination of low-dose ipilimumab and anti-PD1: A real-world experience.

Caio Dabbous Liz,Marcos Rezende Teixeira,Luciana Beatriz Mendes Gomes Siqueira,Jose Augusto Rinck,João Paulo da Silveira Nogueira Lima,Monique Celeste Tavares,Daniel Garcia,Thiago Bueno Oliveira,Marcelo Cavicchioli,Eduardo Lima,João Pedreira Duprat,Milton Jose De Barros E. Silva

18F-FDG-PET/CT response assessment in patients with advanced melanoma treated with combination of low-dose ipilimumab and anti-PD1: A real-world experience.

2021

Caio Dabbous Liz
Marcos Rezende Teixeira
Luciana Beatriz Mendes Gomes Siqueira
Jose Augusto Rinck
João Paulo da Silveira Nogueira Lima
Monique Celeste Tavares
Daniel Garcia
Thiago Bueno Oliveira
Marcelo Cavicchioli
Eduardo Lima
João Pedreira Duprat
Milton Jose De Barros E. Silva

e21533Background: Combination therapy with anti-PD1 and low-dose ipilimumab has shown reduced rate of immune-related adverse effects compared with standard dose used in the Checkmates studies 067 a...

Keywords:

Ipilimumab
in patient
Adverse effect
advanced melanoma
fdg pet ct
Medicine
Oncology
Internal medicine
response assessment
anti pd1
Combination therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations